Viewworks Summary
Core Content
Viewworks is a company that has been analyzed for its financial performance and future growth potential. The document provides a detailed overview of its recent performance, forecasted financials, and valuation analysis, with a particular focus on its medical imaging and industrial-use camera segments.
Main Points
Current Stock Performance
- Current Price: KRW55,500
- Target Price: KRW72,000
- Upside Potential: 29.7%
- Market Cap: KRW555.1b / USD479.61m
- Shares (float): 10,001,865
- 52-week High/Low: KRW72,100 / KRW49,250
- Avg Daily Trading Value (60-day): KRW4.5b / USD3.9m
One-Year Performance
| Period |
Viewworks (%) |
Vs Kosdaq (%pts) |
| 1M |
-4.0 |
-4.2 |
| 6M |
-14.6 |
-17.2 |
| 12M |
10.1 |
13.7 |
Key Changes in Forecasts
| Metric |
New |
Old |
Diff (%) |
| Recommendation |
BUY |
BUY |
- |
| Target Price |
72,000 |
87,000 |
-17.2% |
| 2017E EPS |
2,884 |
3,152 |
-8.5% |
| 2018E EPS |
3,505 |
3,661 |
-4.3% |
Analyst's View
- Despite a slight miss in 2Q performance, the company is expected to rebound with solid results in 3Q.
- The analyst maintains a BUY recommendation due to the company's strong medium-to-long-term growth potential.
Medical Imaging Business
2Q Performance
- Sales: KRW31.4b (vs consensus of KRW31.2b)
- Operating Profit: KRW7.0b (vs consensus of KRW7.6b)
- Net Profit: KRW6.0b (vs consensus of KRW6.4b)
- Operating Margin: 22.3% (down 1.2% pts y-y)
- Medical Imaging Sales: KRW18.4b (up 7.6% y-y)
- FP-DR Detector Sales: KRW15.9b (up 33.4% y-y)
Challenges in 1Q
- Medical-use imaging sales declined due to:
- A 10% drop in ASP for DR detectors.
- Sluggish domestic demand.
- US dollar depreciation affecting competitiveness.
Future Outlook for 2H
- Medical-use imaging sales are projected to grow by 14.8% y-y to KRW50.1b in 2H.
- The US retrofit market is expected to drive growth, with Medicare reimbursement cuts for CR equipment likely to accelerate adoption of DR detectors.
- Viewworks is expected to benefit from the growing US DR market penetration (50% in 2016), with a 31.3% share of its sales coming from this market.
Industrial-Use Camera Sales
- 2Q Sales: KRW13.0b (up 101.7% y-y, down 13.3% q-q)
- 3Q Sales: KRW15.6b (up 31.8% y-y, up 19.4% q-q), which is a quarterly record.
- OLED Industry Capex Hikes: Expected to drive continued growth in industrial-use camera sales.
- Industrial-Use Cameras Account for 40% of Sales: Up from historic peaks of 70-80% for medical-use detectors.
New Products and Market Position
- TFT-based Dynamic Detectors: Viewworks has launched a new product that can capture moving images, making it the world's third seller of such detectors, alongside Varex Imaging and Trixell.
- Market Potential: The global dynamic detector market is valued at KRW300b-400b and is expected to grow at 5% CAGR through 2020.
- Sales Forecasts: Dynamic detector sales are projected to reach KRW9.9b in 2017 and KRW19.6b in 2018.
- Price Advantage: Dynamic detectors are priced 1.5x higher than static detectors, with similar COGS.
Valuation and Market Position
Sum-of-the-Parts Valuation
| Segment |
2017E Net Profit (KRWb) |
P/E (x) |
Note |
| Medical Imaging (A) |
505.8 |
25.0 |
25% premium to x-ray detector sector |
| Industrial Camera (B) |
368.7 |
24.4 |
15% discount to industrial imaging sector |
| Fair Equity Value |
874.5 |
24.7 |
|
Valuation Comparisons
| Company |
2016 Market Cap (KRWb) |
2017E Market Cap (KRWb) |
2018E Market Cap (KRWb) |
P/E (x) 2017E |
| Viewworks |
555 |
555 |
555 |
19.2 |
| Rayence |
321 |
321 |
321 |
17.9 |
| DR Tech |
81 |
81 |
81 |
16.7 |
| Varex Imaging |
1,284 |
1,284 |
1,284 |
19.0 |
| Analogic Corp. |
917 |
917 |
917 |
28.3 |
| Canon |
44,907 |
44,907 |
44,907 |
23.4 |
| Fujifilm |
18,568 |
18,568 |
18,568 |
13.9 |
| Konica Minolta |
4,214 |
4,214 |
4,214 |
9.8 |
| Hama Matsui |
5,084 |
5,084 |
5,084 |
14.9 |
| Basler |
525 |
525 |
525 |
25.6 |
| Teledyne Tech |
4,632 |
4,632 |
4,632 |
24.1 |
Valuation Metrics
| Metric |
2016 |
2017E |
2018E |
| P/E (x) |
22.2 |
19.2 |
15.8 |
| P/B (x) |
5.4 |
4.0 |
3.3 |
| EV/EBITDA (x) |
15.2 |
11.9 |
10.2 |
Conclusion
- Buy Recommendation: Despite a 17.2% drop in the target price to KRW72,000, the analyst maintains a BUY rating due to the company's solid medium-to-long-term growth potential.
- Key Drivers: The medical imaging segment is expected to rebound in 2H, with the US retrofit market and dynamic detector sales as key growth areas.
- Industrial Camera Segment: Expected to continue strong performance due to OLED industry capex and potential orders in China.
- Valuation: Viewworks is currently undervalued relative to its growth prospects and is projected to have a fair value of KRW715.4b, which is 22x forward P/E.